With a particularly active healthcare and life sciences practice, Hogan Lovells (Paris) LLP’s team is recognised for its expertise in matters relating to competition law, regulatory compliance, healthcare data processing, product liability and commercial litigation. At the helm of the practice, Mikael Salmela covers the entire scope of the product lifecycle in the pharmaceutical, biotech and medical device sectors, undertaking matters ranging from advising on clinical trial frameworks to negotiating high-value commercial agreements. Charlotte Damiano is regularly called upon by clients for regulatory and market access matters, as well as representing pharmaceutical and medical device companies in pricing and reimbursement disputes.
Legal 500 Editorial commentary
Mentions
Profile
Work Department
Commercial
Position
Partner
Career
As a partner in the Hogan Lovells' Paris office and a member of our Corporate Commercial practice, Mikael focuses on commercial, regulatory and contractual work. Mikael has considerable experience dealing with a variety of complex and strategic agreements in various industry sectors, such as life sciences, energy and IT. Mikael's experience in regulatory matters covers a wide array of topics, including various consumer products and export controls, with a particular focus on life sciences.
Mikael has in-house counsel experience since he was seconded for several months to an online mass retailer of consumer products and to the French subsidiary of a U.S.-based pharmaceutical company. Mikael was also seconded to our London office for six months.
Languages
English, French, Finnish, German (Basic)
Education
Magistère Juriste d'Affaires/ DJCE, University of Montpellier, 1999
Content supplied by Hogan Lovells (Paris) LLP
Testimonials
Collated independently by Legal 500 research team.
‘A strong team with in-depth expertise on access and commercialization.’
‘Charlotte Damiano is an exceptional expert.’
Key clients
- Alexion Pharma
- Rovi
Work highlights
Assisted Alexion Pharma in a dispute that lasted approximately 10 years, seeking a reversal of the French Supreme Court’s (Cour de Cassation) historic case law on the deduction of rebates paid to the health insurance fund from the turnover of laboratories subject to social security contributions.